Z Benbrahim1, A Berrada2, L Amaadour2, F Zahra El M'rabet2, H Elfatemi3, S Elfakir4, N Mellas2, S Arifi2. 1. Service d'oncologie médicale, faculté de médecine et de pharmacie de Fès, université Sidi Mohammed Ben Abdellah, CHU Hassan II de Fès, route sidi Hrazem, Fès, Maroc. Electronic address: zineb.benbrahim@usmba.ac.ma. 2. Service d'oncologie médicale, faculté de médecine et de pharmacie de Fès, université Sidi Mohammed Ben Abdellah, CHU Hassan II de Fès, route sidi Hrazem, Fès, Maroc. 3. Service d'anatomo-pathologie, faculté de médecine et de pharmacie de Fès, université Sidi Mohammed Ben Abdellah, CHU Hassan II de Fès, Fès, Maroc. 4. Département d'épidémiologie et de santé communautaire, faculté de médecine et de pharmacie de Fès, université Sidi Mohammed Ben Abdellah, Fès, Maroc.
Abstract
OBJECTIVES: The locally advanced breast cancer (LABC) covers large tumor heterogeneity. It consists of non-inflammatory LABC and inflammatory breast cancer (IBC). This study aimed to compare the epidemiological, clinical and pathological, as well as the prognosis of IBC versus non-inflammatory LABC. METHODS: This is a retrospective study of 150 cases of IBC and non-inflammatory LABC collected in medical oncology department of the CHU Hassan II of Fez during a period of 4 years [January 2009-January 2013]. Overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method. Analysis of the various prognostic factors was performed according to the Cox model. RESULTS: IBC represented 28.7% of LABC. The median age was 47 years. The median tumor size was greater in non-inflammatory LABC compared with IBC (9.5 versus 6cm; P=0.0014). Lymph node invasion was more common in the IBC (49.7% versus 45.9%; P=0.01). An SBR grade 3 was more frequently noted in the IBC (P=0.011). The two groups were well balanced with regard to HR, HER2 status and pathologic complete response. Non-inflammatory LABC had the best OS and DFS (24 vs. 22 months; P=0.03 and 18 vs. 17 months; P=0.025 respectively). CONCLUSION: IBC has a worse prognosis compared to non-inflammatory LABC. New therapeutic approaches are needed to improve the prognosis of these patients.
OBJECTIVES: The locally advanced breast cancer (LABC) covers large tumor heterogeneity. It consists of non-inflammatory LABC and inflammatory breast cancer (IBC). This study aimed to compare the epidemiological, clinical and pathological, as well as the prognosis of IBC versus non-inflammatory LABC. METHODS: This is a retrospective study of 150 cases of IBC and non-inflammatory LABC collected in medical oncology department of the CHU Hassan II of Fez during a period of 4 years [January 2009-January 2013]. Overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method. Analysis of the various prognostic factors was performed according to the Cox model. RESULTS: IBC represented 28.7% of LABC. The median age was 47 years. The median tumor size was greater in non-inflammatory LABC compared with IBC (9.5 versus 6cm; P=0.0014). Lymph node invasion was more common in the IBC (49.7% versus 45.9%; P=0.01). An SBR grade 3 was more frequently noted in the IBC (P=0.011). The two groups were well balanced with regard to HR, HER2 status and pathologic complete response. Non-inflammatory LABC had the best OS and DFS (24 vs. 22 months; P=0.03 and 18 vs. 17 months; P=0.025 respectively). CONCLUSION: IBC has a worse prognosis compared to non-inflammatory LABC. New therapeutic approaches are needed to improve the prognosis of these patients.
Keywords:
Cancer du sein inflammatoire; Cancer du sein localement avancé; Facteurs pronostiques; Inflammatory breast cancer; Locally advanced breast cancer; Prognostic factors